Tag Archives: innovation

Biochemistry

Biochemical Diagnostic Reagent Market | Covid-19 Impact | Demand, Cost Structures, Latest trends, and Forecasts to 2024 | Key Players: Roche, Siemens…

Biochemical Diagnostic Reagent Market with Covid-19 Impact Analysis: Forecast to Show Spurring Growth by 2020-2024 to its research database. The global Biochemical Diagnostic Reagent Market research report is an output of a brief assessment and an extensive analysis of practical data collected from the global Biochemical Diagnostic Reagent market. The data are collected on the basis of industrial drifts and demands related to the services & products. The meticulously collected data offers for the process of effortless strategic planning. It also helps in creating promising business alternatives.

Free Sample Report + All Related Graphs & Charts @ https://www.acquiremarketresearch.com/sample-request/362392/

A perfect demonstration of the recent expansions and innovative technological resolutions offer our customers the liberty to develop their decision-making skills. This ultimately helps to work with perfect business alternatives and apply elegant implementations. The global Biochemical Diagnostic Reagent Market report emphasizes the latest developments, growth, new opportunities, and dormant tricks. It provides an all-inclusive stance of the global Biochemical Diagnostic Reagent Market. Requirement proportion and innovation of modern technologies are some of the key factors covered in the global Biochemical Diagnostic Reagent Market report.

Our Free Complimentary Sample Report Accommodate a Brief Introduction of the research report, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology.

This helps to understand the overall market and to recognize the growth opportunities in the global Biochemical Diagnostic Reagent Market. The report also includes a detailed profile and information of all the major market players currently active in the global Biochemical Diagnostic Reagent Market. The companies covered in the report can be evaluated on the basis of their latest developments, financial and business overview, product portfolio, key trends in the market, long-term and short-term business strategies by the companies in order to stay competitive in the market.

Download Free PDF Report Brochure @ https://www.acquiremarketresearch.com/sample-request/362392/

Some of the Major Market Player Profile Included in This Report is:

Roche, Siemens Healthineers, Beckman Coulter, Randox, BioSino, Beijing Leadman Biochemistry, FosunPharma, Beijing Strong Biotechnologies, Dojindo Laboratories, Sysmex, KAINOS Laboratories, DAAN Gene

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into Liquid Double Reagent, Dry Powder Double Reagent .

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including Hospital, Clinic, Laboratory.

The greater part of the data gathered is presented in graphical form along with the related statistics. The global Biochemical Diagnostic Reagent Market report demonstrates the functioning of the main market players, suppliers, and dealers in detail. The report also highlights the restraints and drivers impacting the global Biochemical Diagnostic Reagent Market.

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

(*If you have any special requirements, please let us know and we will offer you the report as you want.)

The report analyzes various decisive constraints such as item price, production capability, profit & loss statistics, and transportation & delivery channels influencing the global Biochemical Diagnostic Reagent Market. It also covers the analysis of other important elements such as market demands, advancements, and product developments, various organizations, and processes impacting the global Biochemical Diagnostic Reagent Market. The global Biochemical Diagnostic Reagent Market research report emphasizes a variety of modifications done that improve the work process of the global Biochemical Diagnostic Reagent Market.

Grab Your Report at an Impressive Discount (Use Corporate email ID to Get Higher Priority) @ https://www.acquiremarketresearch.com/discount-request/362392/

A methodically structured Biochemical Diagnostic Reagent Market research report is based on the primary and secondary resource. It portrays the data collected in a more communicative and expressive way allowing the customer to develop a well-structured plan to develop and expand their businesses in the estimated duration.

Promising Regions & Countries Mentioned in The Biochemical Diagnostic Reagent Market Report:

North America: United States, Canada, and Mexico.South & Central America: Argentina, Chile, and Brazil.Middle East & Africa: Saudi Arabia, UAE, Turkey, Egypt and South Africa.Europe: UK, France, Italy, Germany, Spain, and Russia.Asia-Pacific: India, China, Japan, South Korea, Indonesia, Singapore, and Australia.

Buy Full Copy Global Biochemical Diagnostic Reagent Report 2020-2024 @ https://www.acquiremarketresearch.com/buy-now/362392/?price=su

COVID-19- Current Scenario & Potential Impact

Various communities and companies are doing their best to function and perform, and eventually cope with the challenges raised by COVID-19 pandemic. The COVID-19 pandemic had a negative impact on the market size for the year 2020, with small and medium scale companies struggling to sustain their businesses in the near-term future. Industry leaders are now focusing to create new business practices to deal with crisis situations like COVID-19 pandemic.

The report presents a strategic analysis of the Biochemical Diagnostic Reagent market through key drivers, challenges, opportunities, and growth contributors. Further, the market attractiveness index is provided based on five forces analysis.

The Biochemical Diagnostic Reagent market delivers value to customers through reliable market size for 2019 on the basis of demand and price analysis. The report presents near term and long term forecast of the addressable Biochemical Diagnostic Reagent market size to 2024.

(We customize your report according to your research need. Ask our sales team for report customization. [emailprotected])

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About us:

Acquire Market Research is a market research-based company empowering companies with data-driven insights. We provide Market Research Reports with accurate and well-informed data, Real-Time with Real Application. A good research methodology proves to be powerful and simplified information that applied right from day-to-day lives to complex decisions helps us navigate through with vision, purpose and well-armed strategies. At Acquire Market Research, we constantly strive for innovation in the techniques and the quality of analysis that goes into our reports.

Contact Us:

Sally Mach555 Madison Avenue,5th Floor, Manhattan,New York, 10022 USAPhone No.: +1 (800) 663-5579Email ID: [emailprotected]

Go here to see the original:
Biochemical Diagnostic Reagent Market | Covid-19 Impact | Demand, Cost Structures, Latest trends, and Forecasts to 2024 | Key Players: Roche, Siemens...

Neuroscience

Madrid-based Kymatio raises 725K to expand its cybersecurity tools for employees – EU-Startups

Spanish startup Kymatio, the SaaS platform that manages cyber risk for employees, has increased its first round of investment by 40% to accommodate two new partners, Banco Sabadell, BStartup and the JME Ventures fund. These new investors joined the round led by The Crowd Angel, which also had support from Wayra, Telefnicas open innovation hub, and prominent business angels such as Enrico Raggini.

Kymatio, founded in 2017, addresses cybersecurity from one of the most significant parts of risk: that associated with people. According to Kymatio, around 60% of security incidents involve internal personnel. The startup states that organizations face massive losses in domestic incidents with an average cost of 8 million in large corporations and 40K in the case of SMEs.

As stated Fernando Mateus, CEO of Kymatio: 70% of organizations have suffered an internal incident. Kymatio determines the cyber risks being faced, and assesses the level of awareness of each employee in the main areas of cybersecurity, to automatically deploy measures focused on customized strengthening of the individuals in those areas of risk, and enhancing the role of the first and last line of defense that employees have.

With this round, Kymatio aims to fuel its sales and boost the product, adding functionality that identifies, analyses, and overall covers everything an organization needs to address the security risks linked to information and employees.

According to Yolanda Prez, Director of BStartup: Cybersecurity is a field of growing importance to businesses and with the expansion of remote work it will be even more relevant. Kymatio allows a holistic prevention strategy, tackling the problem from the human factor by the means of state-of-the-art techniques and innovative technology. At Banco Sabadell we hope to be able to contribute to the growth of this company that has a first-class team and product.

As indicated by Lourdes lvarez de Toledo , Principal at JME Venture Capital: Kymatio is a pioneer in addressing vulnerability and internal cyber risk threats by coupling technology with neuroscientific tools. This position, together with the team that leads it, as well as the distribution agreements that it is carrying out, are the factors that make us trust in the future success of this company.

To date, Kymatio has had the support and validation of important cybersecurity institutions, such as INCIBE, and leading neuroscience research centers, such as the Autonomous University of Madrid. The startup was acclaimed winner of the first call for Cybersecurity by ElevenPaths , and the Ministry of Science and Innovation, granted the NEOTEC grant from the CDTI for technology companies of 160K.

Go here to read the rest:
Madrid-based Kymatio raises 725K to expand its cybersecurity tools for employees - EU-Startups

Cell Biology

CONAMAX(TM): Promising Antibody-based Therapy Breakthroughs are Brewing at Conagen – SynBioBeta

In recent years, leveraging biology and engineering has led to incredible strides in combating human disease. In particular, we are able to develop and use antibodies to target a range of conditions, from cancer and cardiovascular ailments to skin disease and Ebola. Immunotherapy is rapidly becoming the most promising approach to eliminate cancerous cells. Indeed, the immunotherapy and antibody-drug conjugate market based on blockbuster monoclonal antibodies is worth USD $100 billion.

Monoclonal antibodies are just one type of glycoprotein a diverse class of molecules that are just like regular proteins but with short chains of glycans (sugars) attached to them. Glycoproteins perform tasks critical for the human bodys reproductive, digestive, endocrine, and immune systems. Whether the glycoprotein is erythropoietin (stimulating red blood cell production in bone marrow) or a B-cell-bound antibody (driving immune responses), this class of molecules holds vast potential to be leveraged for engineering and advancing human health something that has been clearly demonstrated by the current multitude of candidate COVID-19 antibody therapeutics.

While therapeutic glycoproteins are a critical key for further developing promising immunotherapies, the development and production of these molecules has been stubbornly limited due to their complex structures. The challenges of glycoprotein synthesis are varied. It is often difficult to determine the structure of the glycoproteins carbohydrates and separate the various forms into pure components because of the heterogeneity of these side chains. Glycosylation is a more diverse and complex posttranslational change compared to various other functional group reactions; coupling this with glycoproteins large size (typically over 15 kilodaltons) and the branched structure of carbohydrate chains, these molecules are chemically challenging targets. These factors have limited the commercial glycoprotein industry to fragile mammalian cell systems that are next to impossible to scale to the same levels as are employed by more cost-sensitive industries.

Until now, that is. The synthetic biology techniques of today are making this problem much more tractable.

Last August, Conagen, a vertically integrated synthetic biology company located in Bostons biotech corridor, announced that it acquired a fermentation-based technology for the production of therapeutically useful glycoproteins, including several patents covering the platform. This is significant because glycoproteins are anything but straightforward to make.

There are two major types of glycans which are bound to glycoproteins: N-linked and O-linked, each of which can exist in a variety of forms and which differ in their locations on a glycoprotein. It is this structural divergence that leads not only to the diverse functional capabilities and distinctions between different glycoproteins, but often to different functions of the same glycoprotein when comprised of different glycans. It is also what has made it difficult to produce glycoproteins via industrial fermentation thus far; engineering a microbe to express glycoproteins with the necessary and optimal glycostructures and to do it robustly and at scale has been a nearly impossible task. But Conagen is uniquely positioned to be the first company to crack the code.

Most antibody-based therapies use monoclonal antibodies to target a wide array of diseases including cancer, neurodegeneration, autoimmune disorders, and infectious diseases like COVID-19. Traditionally, these antibodies are commercially produced in mammalian systems, such as Chinese hamster ovary (CHO) cells. Some improved technologies have made it possible to exceed productivities of 2 g/L/day in CHO cells producing some antibodies. However, remaining challenges still include high production costs, long optimization time and quality concerns.

Conagens new proprietary Conamax(TM) platform promises to achieve productivity upward of 1 g/L/day in a fast and sustainable way. Production of several therapeutic monoclonal antibodies has already been demonstrated in the system. Furthermore, the increased efficiency resulting from the greater scalability and robustness of this novel platform will also translate to surprisingly lower production costs, reducing the economic burden for the patients who need these critical treatments a necessary focus as the high price of biopharmaceuticals and other drugs dominate news cycles and elections.

The Conamax(TM) platform is uniquely suited for making antibodies. One of the most exciting features of this host organism is its ability to express glycoproteins harboring homogenous glycostructures which promote the desired immune cell functions, says Vice President of Innovation, Casey Lippmeier. This is a very unusual feature to find in a robustly fermentable microbe. It is also advantaged by its ability to tolerate the engineering required to customize these glycostructures while preserving the microbes robustness.

At present, Conagen plans to expand this technology and others towards large-scale manufacturing of solutions to combat COVID-19. We are thinking of a much higher production scale than what is currently achievable, said Lippmeier, as a key panelist in SynBioBetas COVID-19 antibodies roundtable on April 17, 2020.

It should come as no surprise that Conagen is making waves in this space. The company has a deep-rooted history in the biochemistry of botanical product biosynthesis and is driven by an unwavering motivation to uncover metabolic pathways for developing natural products and molecules closest to what nature produces. Much of the companys innovation is facilitated by its extensive microbial platforms, which leverage synthetic biology to rationally engineer and improve upon nature. The companys vertically integrated systems allow for the rapid movement of microbial strains to the metric-ton scale, effectively and efficiently controlling quality, cost, and puritynot an easy feat for most fermentation labs.

Their platform has already seen the introduction of the next generation of rebaudioside-based sweeteners, is enabling chemical giant BASF to scale fermentation of vanillin, and is also being leveraged to produce natural molecules that may promote healthy aging. With this newest addition to their portfolio, the company can now address one of the most significant challenges to realizing promising new glycoprotein-based therapeutics for a range of conditions.

The increased efficiency resulting from increased scales will also translate to reduced production costs, reducing the economic burden for the patients who need these critical treatmentsa necessary focus as pharmaceutical companies and predatory drug pricing dominate news cycles and elections. This concern is more evident than ever, especially as the development and manufacturing of antibodies to treat COVID-19 demand the utmost speed; Conagens Conamax(TM) platform presents a tantalizing opportunity to disrupt traditionally slower production timelines and therefore bring drugs to market as fast as possible to better serve patients.

Conagen has an established history of bringing new innovations to market. The companys ethos rooted in sustainability extends its future and potential far beyond rebaudiosides, vanillin, or even glycoproteins. Its world-scale production capabilities, unique microbial fermentation platforms, and products already on the market will ensure its continued growth and success for years to come. Conagen will continue to innovate the future of biotechnology, producing molecules closest to what nature develops at the nexus of science, the earth, and health.

See the original post here:
CONAMAX(TM): Promising Antibody-based Therapy Breakthroughs are Brewing at Conagen - SynBioBeta

Immunology

Collaborating in Innovative Medical R&D to combat the pandemic, Alphamab Oncology and Institut Pasteur Shanghai Announce Partnership to Co-develop…

DetailsCategory: AntibodiesPublished on Wednesday, 10 June 2020 11:06Hits: 223

SUZHOU, China I June 9, 2020 I Alphamab Oncology (stock code: 9966 HK) announced that Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ("Jiangsu Alphamab"), a wholly-owned subsidiary of the Company, has entered a partnership agreement with Institut Pasteur of Shanghai, Chinese Academy of Sciences ("Institut Pasteur Shanghai") on the co-development, manufacturing and commercialization of therapeutic antibody for Corona Virus Disease 2019 (COVID-19) worldwide.

According to a report on June8, more than 7.10 million people have been diagnosed with COVID-19 infection worldwide, but there are still no vaccines or medicines available for prevention or treatment. Neutralizing antibody targeting proteins on the surface of virus can effectively inhibit the virus' binding and entry into target cells to block infection, therefore it can be considered to be useful to protect or treat patients with COVID-19 infection. Among various potential solutions, the optimized mixed antibodies solution not only amplify the therapeutic effect due to synergistic effect, but also can solve the virus escaping issue due to COVID-19 virus' mutation, and minimizes the risk of "Antibody-dependent enhancement".

This cooperation will fully leverage not only Institut Pasteur Shanghai 's prowess in research and development, and prior research findings in the area of infectious diseases, but also Alphamab Oncology's strong R&D and its proprietary Mixed Antibodies Platform, to develop COVID-19 neutralizing antibody with good safety and high neutralizing activity, complete clinical trials soon to provide antibody treatment options, effectively improve the prevention capabilities, reduce the mortality rate, and contribute to disease prevention and control for China and the world. Meanwhile, Pasteur's global R&D network could also help expedite the completion of clinical trial.

According to the agreement, Alphamab Oncology and Institut Pasteur Shanghai will form a joint project team. Alphamab Oncology is responsible for providing its proprietary Mixed Antibodies Platform, constructing humanized antibodies and recombinant engineered cell lines, carrying out PK study, clinical trials, manufacturing, and commercialization. Institut Pasteur Shanghai is responsible for the comprehensive analysis of neutralizing activity of COVID-19 antibodies.

Dr. Ting Xu, Founder, Chairman and CEO of Alphamab Oncology commented, "Since the end of 2019, COVID-19 has ravaged the world and has become the major global public health issue. We plan to partner with Institut Pasteur Shanghai by leveraging our proprietary antibody technology platform, extensive experiences in antibody drug R&D and established manufacturing platform to accelerate the development of COVID-19 antibodies to combat COVID-19, prevent subsequent outbreaks and contribute to the further prevention and control of this epidemic."

Dr. Hong Tang, Director General and Legal Representative of Institut Pasteur Shanghai commented, "Since the outbreak of the Coronavirus, the Institut Pasteur Shanghai has been focusing on R&D Projects including virus detection and origin tracing, antibody drug and vaccine, and has achieved quite a few progress. This partnership with Alphamab Oncology on COVID-19 neutralizing antibody drughas demonstrated not only the innovation capability of our research and development team, but also a result of the reform of Chinese Academy of Sciences and the capable platform of Shanghai Science and Innovation Center. Our institute will collaborate with industry players to accelerate drug development and contribute to the prevention and control of pandemic as soon as possible."

About Alphamab Oncology

Alphamab Oncology is a biopharmaceutical company focusing on innovative biologics medicine for oncology. On December 12, 2019, the Company was listed in the mainboard of Hong Kong Stock Exchange with stock code 9966.

Alphamab has fully integrated proprietary biologics platforms in bi-specifics and protein engineering. Its highly differentiated in-house pipeline consists of eight anti-cancer drug candidates, four of which have advanced into Phase I III clinical development phases in China, US and Japan.

The Company also has state-of-the-art manufacturing capability designed and built to meet NMPA and EU/FDA's cGMP standards.

Alphamab Oncology is committed to further develop its robust pipeline in oncology/immunology to benefit patients around the world. Visit http://www.alphamabonc.com for more information.

About Institut Pasteur Shanghai

Institut Pasteur of Shanghai of Chinese Academy of Sciences was established in October 11, 2004.It is the only national research institute dedicated to the basic research and development of relevant technologies for human infectious diseases within the Academy. The Institute focuses on key scientific subject such as the fundamental laws of pathogenic microorganisms' activities, and the pathogenic mechanism of major infectious diseases, to promotes the innovation and development of etiology, immunology and vaccinology to solve key issues such as the discovery of pathogen and biological treatment (antibodies, vaccines, etc. ), with a focus on providing scientific and technological support and solutions for public health and biosecurity of China.It is actively participating the building of Shanghai Science and Innovation Center. The infectious diseases' prevention and treatment platform, a functional platform which it is responsible for, will provide solid scientific support for the prevention and control of infectious diseases in Shanghai and Yangtze River Delta Region in China.

SOURCE: Alphmab

Continue reading here:
Collaborating in Innovative Medical R&D to combat the pandemic, Alphamab Oncology and Institut Pasteur Shanghai Announce Partnership to Co-develop...

Neuroscience

Neuroscience Market 2024 Expected to reach Highest CAGR including major key players GE Healthcare, Siemens Healthineers, Noldus Information…

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the NeuroscienceMarket which would mention How the Covid-19 is Affecting the Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Key Regions and Proposal for Neuroscience Market Players to battle Covid-19 Impact.

The NeuroscienceMarket report is one of the most comprehensive and important data about business strategies, qualitative and quantitative analysis of Global Market. It offers detailed research and analysis of key aspects of the Neuroscience market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the Neuroscience market.

Top Leading players covered in the Neuroscience market report: GE Healthcare, Siemens Healthineers, Noldus Information Technology, Mightex Bioscience, Thomas RECORDING GmbH, Blackrock Microsystems, Tucker-Davis Technologies, Plexon, Phoenix Technology Group, NeuroNexus, Alpha Omega and More

Get PDF Sample Report With Impact of COVID-19 on Neuroscience [emailprotected] https://www.marketinforeports.com/Market-Reports/Request-Sample/83545

The report offers clear guidelines for players to cement a position of strength in the global Neuroscience market. It prepares them to face future challenges and take advantage of lucrative opportunities by providing a broad analysis of market conditions. the global Neuroscience market will showcase a steadyCAGR in the forecast year 2020 to 2024.

Product Type SegmentationWhole Brain ImagingNeuro-MicroscopyElectrophysiology TechnologiesNeuro-Cellular ManipulationStereotaxic Surgeries

Industry SegmentationHospitalsDiagnostic LaboratoriesResearch InstitutesOther

Our Complimentary Sample Neuroscience market Report Accommodate a Brief Introduction of the research report, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology.

Inquire and Get Up to 30% DiscountBy Clicking Here!https://www.marketinforeports.com/Market-Reports/Request_discount/83545

Regions Covered in the Global Neuroscience Market: The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Years Considered to Estimate the Neuroscience Market Size:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year: 2020-2024

Highlights of the Report: Accurate market size and CAGR forecasts for the period 2019-2024 Identification and in-depth assessment of growth opportunities in key segments and regions Detailed company profiling of top players of the global Neuroscience market Exhaustive research on innovation and other trends of the global Neuroscience market Reliable industry value chain and supply chain analysis Comprehensive analysis of important growth drivers, restraints, challenges, and growth prospects

For More Information:https://www.marketinforeports.com/Market-Reports/83545/Neuroscience-market

Customization of the Report:Market Info Reports provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Get Customization of the [emailprotected]:https://www.marketinforeports.com/Market-Reports/Request-Customization/83545/Neuroscience-market

Contact Us:Mr. Marcus KelCall: +1 415 658 9988 (International)+91 84 839 65921 (IND)Email: [emailprotected]Website: http://www.marketinforeports.com

See more here:
Neuroscience Market 2024 Expected to reach Highest CAGR including major key players GE Healthcare, Siemens Healthineers, Noldus Information...

Human Behavior

Survival Instincts and Lies from the Top: How Crises Alter Human Behavior – CBD Today

By now, you probably have experienced the long lines and empty shelves at grocery and warehouse stores. Or you may have tried to buy staples such as canned food and toilet paper online from companies such as Walmart, Target, and Amazon only to discover they are sold out.

This seems unprecedented, but a look back at our history helps explain the phenomenon.

Sander van der Linden, an assistant professor of social psychology at Cambridge University, said a fear contagion phenomenon has taken hold in America. When people are stressed their reason is hampered, so they look at what other people are doing, he said. If others are stockpiling, it leads you to engage in the same behavior. People see photos of empty shelves and regardless of whether its rational, it sends a signal to them that its the thing to do.

As humankind has become more civilized and technological advancements have changed our lives, the survival instinct can become dormant. However, as current events clearly indicate, this survival behavior quickly can be reignited and spread like wildfire.

A look back to the Great Depression can cast some light on human behavior during a crisis.

John Montgomery Ph.D., wrote about this human condition. When we live in environments, such as modern cities, that are drastically different from the environments that were biologically adapted for, we become subject to various evolutionary mismatch effects that can be extremely detrimental to our physical and emotional health, he wrote. Perhaps the most important consequence of this mismatch is that we become highly prone to being triggered repeatedly and unnecessarily into various states of survival mode.

A look back to the Great Depression can cast some light on human behavior during a crisis. As conditions worsened over the course of the Depression and people increasingly lost confidence in banks, they started withdrawing their money in large numbers. Recognizing the crisis, in 1932 President Herbert Hoover denounced traitorous hoarding and organized an anti-hoarding drive. He also delivered a radio address pleading for people to stop hoarding and cease converting bank deposits into cash. Few listened.

Why policy and leadership matter

In the aftermath of the Great Depression, many argued the financial sector was so important it needed to be closely monitored and regulated. For a while it was. But then Republican administrations continued to wind back many of the regulations that kept financial institutions from gorging themselves to death. The lack of oversight ultimately led to the Great Recession of 2007 2009.

After then-President George W. Bush left office, President Barack Obama implemented new regulations aimed at keeping the banking system healthy. However, those safeguards again were rolled back once Donald J. Trump took office.

Early in his administration, as if a thank you to Wall Street, Trump signed a directive aimed at dismantling the Dodd-Frank Wall Street Reform and Consumer Protection Act, crafted by the Obama administration in response to the 2008 economic meltdown. Trump also signed a memorandum to reverse the fiduciary rule, which requires brokers to act in their clients best interest, rather than seek the highest profits for themselves, when providing financial planning advice.

Trumps action on the fiduciary rule, which Democrats and consumer groups immediately denounced, allows financial advisors to steer unsuspecting clients toward investments that may enrich the broker but not be in the clients best interest.

The great disconnect from the facts

The premise that the Republican party is the party of fiscal conservatives and the Democrats are fiscal numbskulls just doesnt fit with the facts. In fact, during the past thirty-nine years, all the United States recessions occurred under Republican administrations.

Moreover, Americas deficit spending, once anathema to Republicans, has increased more under recent Republican administrations than under Democratic presidencies.

Reagan took the federal deficit from $70 billion to $175 billion. George H.W. Bush took it to $290 billion. President Bill Clinton reduced it to zero. George W. Bush took it from zero to $1.4 trillion. Obama halved it to $584 billion. The Trump administration has raised it back to more than $1 trillion.

The U.S. is now in another crisis. The health of the countrys citizens and economy is under attack. People are hoarding supplies, and a survivalist mentality has infected the populace.

In this election year, voters can decide whether we have thoughtful, intelligent, compassionate leaders in Washington or boisterous, dishonest fools on the hill. The choice may be at the very heart of our survival.

Randall Huft is president and creative director at Innovation Agency, an advertising, branding, and public relations firm specializing in the cannabis industry. While working with blue-chip companies including AT&T, United Airlines, IBM, Walgreens, American Express, Toyota, and Disney, he discovered what works, what doesnt, and how to gain market share.

Read more:
Survival Instincts and Lies from the Top: How Crises Alter Human Behavior - CBD Today

Biochemistry

Researchers are developing portable device to detect the presence of PFAS in water – News-Medical.Net

Potentially harmful man-made chemicals used in firefighting foam and consumer products have contaminated groundwater and even private wells near military, industrial and disposal sites across the country-; including Joe Foss Field and Ellsworth Air Force Base in South Dakota.

Currently, scientists must take water and soil samples from the sites to the lab and use expensive instruments to detect the presence of per- and poly-fluoroalkyl substances, known as PFAS, said South Dakota State University chemistry and biochemistry professor Brian Logue.

"There currently is not a good way to take that technology to the field."

Logue and research scientist Randy Jackson of Seacoast Science, Inc. are developing a portable device to detect the presence of PFAS in water, sediment, and soil through a two-year, $300,000 Phase II Small Business Innovation and Research grant from the Environmental Protection Agency.

This is part of the agency's efforts to help states and communities identify and address PFAS contamination and thereby protect the nation's drinking water.

PFAS is a family of more than 3,000 chemicals used to make water- and stain-resistant fabrics, carpets, and clothing as well as nonstick cookware. They are in paints, cleaning products, some food packaging, and firefighting agents.

Some are also present in coatings for electronic components and solar panels as well as in medical devices.

The researchers are expanding the technology they developed for a portable cyanide detection device. That project was part of Jackson's doctoral work, which he completed under Logue's tutelage.

PFAS has been called "forever chemicals" because they are very stable-; they persist both in the environment and in the human body.

For most organic compounds, there are bacteria or oxidative or hydrologic chemical reactions that degrade them into less toxic compounds.However, PFAS is very difficult to degrade, so they stick around for a long time unless you actively try to degrade them."

Brian Logue, Professor of Chemistry and Biochemistry, South Dakota State University

"They are engineered to break down slowly with a half-life in water of more than 92 years," Jackson said.

"Their high water solubility makes them especially dangerous they can enter and be transported by groundwater into the drinking water supply."

Ellsworth Air Force Base near Rapid City is one of the EPA's Superfund cleanup sites, due to PFAS contamination from the foam used to extinguish aircraft fires.

In 2017, the U.S. Air Force reported that PFAS groundwater contamination had spread beyond the base into local private drinking water wells.

Last June, the City of Sioux Falls filed suit in U.S. District Court against a number of chemical companies, including 3M and DuPont, because PFAS has contaminated surface and groundwater, soil, and sediment in the portion of Joe Foss Field leased to the South Dakota Air National Guard.

Human exposure can occur through contaminated water, soil, and air. In 2007, the Centers for Disease Control and Prevention, which monitors human exposure to environmental chemicals, found 98% of Americans have detectable levels of PFAS in their blood.

The substances also accumulate in the liver and kidneys.

Scientists have just begun studying their impact on human health; however, changes in liver, thyroid, and pancreas function and hormone levels occur in animals exposed to high levels of PFAS, according to the Agency for Toxic Substances and Disease Registry.

In Phase I, which was completed last year, the researchers showed they can measure/detect PFAS in water.

"We came up with the idea to degrade PFAS to smaller components that are not as difficult to analyze, then isolate them and detect them fluorometrically like we detect cyanide in our lab," Logue explained. However, he noted, though the concept is similar, "all the details are quite a bit different."

Degrading the PFAS into smaller components is relatively easy, but selectively isolating these components from the matrix is challenging, he explained.

Furthermore, the researchers had to synthesize chemicals that would react, or fluoresce, in the presence of the smaller components.

"We found a good fluorometric agent in Phase I, did some degradations, and got some good results," Logue said. Two doctoral students are also working on the project. During Phase II, the researchers will put the proof of concept into practice.

"Now it is time to take the core technology and create a sensor to do this analysis," he added.

This will involve optimizing the process, determining exactly which chemistry to use and the time required to detect PFAS.

"We've focused so far on water, which is the easiest matrix," Logue said. "Once the sensor works well with water, there are ways to prepare soil samples to use that same technology."

Based on the near-real-time analysis, the scientists will then know whether the site warrants further assessment.

In addition, Logue sees the possibility of further applications for the sensor because industries use similar compounds.

The rest is here:
Researchers are developing portable device to detect the presence of PFAS in water - News-Medical.Net

Cell Biology

Shanghai Cell Therapy Group Launches Collaboration with USC researcher to Improve the ex vivo Expansion of Hematopoietic Stem Cells for Clinical…

SHANGHAI, May27, 2020 /PRNewswire/ -- Shanghai Cell Therapy Group (SHCell) recently entered intoa six-year research collaborative project with Professor Qi-Long Ying from the University of Southern California (USC). Through the project, sponsored by $3.6 million from the Baize Plan Fund, the Ying laboratory aims to develop conditions for the long-term ex vivo expansion of mouse and human hematopoietic stem and progenitor cells.

"Hematopoietic stem cells, or HSCs, are found in the bone marrow of adults," said Professor Qijun Qian, CEO of Shanghai Cell Therapy Group. "HSCs have the ability for long-term self-renewal and differentiation into various types of mature blood cells, and for rebuilding normal hematopoiesis and immune function in patients. They also have enormous potential to treat diseases, including tumors, autoimmune diseases, severe infectious disease, and inherited blood diseases, and to combat the effects of aging."

This research project will be conducted and supervised by Professor Qi-Long Ying, a Professor of Stem Cell Biology and Regenerative Medicine at the Keck School of Medicine of USC. Professor Ying's pioneering stem cell research has won international acclaim, including the 2016 McEwen Award for Innovation, the highest honor in the field.

"We'll develop and optimize culture conditions for the long-term ex vivo expansion of HSCs," said Professor Ying. "We'll also test combinations of basal media, small molecules, cytokines and growth factors, and characterize ex vivo expanded hematopoietic stem and progenitor cells. These cells will then be genetically modified and tested for their potential to treat different diseases, including blood disorders and cancers."

Professor Andrew P. McMahon, Director of Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research of USC, added: "Stem cell biology represents an exciting area in medicine with great therapeutic potential. I am delighted SHCell is supporting Professor Ying. A breakthrough in the ability to propagate and manipulate HSCs will have lasting clinical significance."

The project also plans to build animal models of different blood diseases and cancers and test the safety and effectiveness of genetically modified hematopoietic stem and progenitor cells before clinical translation. SHCell will actively explore clinical applications of hematopoietic stem and progenitor cells in the treatment of cancers or blood diseases.

As SHCell's first overseas collaboration, this project aims to advance the goals of the Baize Plan: to provide first-class cell treatments and cell therapies at an affordable price to cure cancer and increase life expectancy. SHCell hopes that this project will also accelerate original scientific breakthroughs in the stem cell field.

Shanghai Cell Therapy Group

Founded in 2013, Shanghai Cell Therapeutics Group Co., Ltd is located at the Shanghai Municipal Engineering and Technology Research Center, which was established by the Shanghai Science and Technology Commission. With a mission of "changing the length and abundance of life with cell therapy", SHCell has created a closed-loop industrial chain and an integrated platform for cell treatment and cell therapy. It comprises cell storage, cell drug research and cell clinical transformation with cell therapy as its core business.

The Baize Plan was proposed in 2016 by Wu Mengchao, an Academician of the Chinese Academy of Sciences (CAS) and initiated by Professor Qian, aiming to provide first-class cell treatments and cell therapies at an affordable price with the goal of curing cancers and increasing life expectancy. The Baize Plan Fund was created by the Shanghai Cell Therapy Group to realize the vision of the Baize Plan.

University of Southern California (USC)

Founded in 1880, the University of Southern California is one of the world's leading educational and research institutions, and also the oldest private research university in California. Located in the heart of Los Angeles, the University of Southern California comprises 23 schools and units, and students are encouraged to explore different fields of study. The University of Southern California ranked #22 in National Universities in the 2020 edition of Best Colleges, published by U.S. News & World Report.

For more information, visit http://www.shcell.com/

See original here:
Shanghai Cell Therapy Group Launches Collaboration with USC researcher to Improve the ex vivo Expansion of Hematopoietic Stem Cells for Clinical...

Neuroscience

Photo gallery The winners: Cool Science Images 2020 – University of Wisconsin-Madison

Eyeball-licking geckos, wiggling brain cells and a whole planets worth of weather are among the winners in the University of WisconsinMadisons 10th Cool Science Image Contest.

The quality of the images and videos produced on campus by scientists and people passionate about science is always so impressive, says Terry Devitt, a judge and one of the founders of the contest. It is always a very hard job, but a very enjoyable one, to choose the best among them.

A panel of nine experienced artists, scientists and science communicators judged the scientific content and aesthetic and creative qualities of the 101 images and videos entered in the 2020 version of the contest, which began as part of The Why Files, one of the first popular science news websites.

Cameron Batchelor and Ethan Parrish, graduate students, Geoscience, for a look at the climate-describing bands of color in a slice of stalagmite.

Natalie Betz, associate director, UWMadison Master of Science in Biotechnology, and Anya Wolterman, Macalester College undergraduate geology student, for their section of rock from a rift in the Earths crust in the Lake Superior region.

Caitlin Carlson, graduate student, Department of Bacteriology, for a view of a pair of leaf cutter ants sniffing out each others pheromone thumbprint.

Collin Roland, graduate student, and Lucas Zoet, assistant professor, Department of Geoscience, for a birds-eye view of bluff erosion on the Lake Michigan shore.

Guilherme Gainett, graduate student, and Prashant P. Sharma, assistant professor, Department of Integrative Biology, for an electron micrograph of the spiny leg of a new species of spider.

Ran Zhang, scientist, and Dalton Griner, graduate student, Department of Medical Physics, for an X-ray of flowers used to test and improve mammograms.

Nisha Iyer, postdoctoral fellow, Wisconsin Institute for Discovery, for a picture of a crested gecko licking its own eyeball.

Robert Morgan, graduate student, and Keith Bechtol, assistant professor, Department of Physics, for a snapshot of thousands of distant galaxies made while hunting for the source of a single subatomic particle.

Michael Petersen, Edward Williams and Ray Collier, all staff of the Wisconsin Crop Innovation Center; and Frank McFarland, graduate student, Department of Agronomy, for their image of the first transgenic hemp plants.

Miranda R. Sun, research specialist, Department of Comparative Biosciences, for a brightly colored section of a developing mouse embryo.

Rick Kohrs, instrument technologist, Space Science and Engineering Center, whose animation of 90,000 satellite images shows a full year of Earths weather.

Chris Morrow and Tiaira Porter, graduate students, Department of Neuroscience, for a video capturing the movement of neural stem cells switching from dormancy to activity.

STORY CONTINUES AFTER GALLERY

1 This slice of stalagmite at 250,000 years old, the oldest dated stalagmite in the Midwest is being used to study the climate of ancient mid-continental North America. The colored layers reflect changes in soil above the cave in which the stalagmite formed, with rich soil (and thicker vegetation) revealed in deeper orange bands and less organic matter (and fewer plants) in light green.

Cameron Batchelor, and Ethan Parrish, graduate students, GeoscienceDigital camera

2 This thin section of troctolite, an igneous rock composed of feldspar and olivine, was collected near Duluth, Minnesota, from the Proterozoic Midcontinent Rift. The rift is a tear in the Earths crust caused by continental plates colliding in the Lake Superior region. Polarized light accentuates vivid colors.

Natalie Betz, associate director, UWMadison Master of Science in Biotechnology; Anya Wolterman, Macalester College undergraduate geology studentPetrographic microscope

3 Each colony of leaf cutter ants has a unique chemical thumbprint, a combination of pheromones that members of the colony can recognize as their own. These two Acromyrmex echinatior ants from different colonies are inspecting each others pheromone signatures.

Caitlin Carlson, graduate student, BacteriologyDigital camera with macro lens

4 Storm-driven Lake Michigan waves cut away bluffs in Warnimont Park in Cudahy, Wisconsin, while the freeze and thaw of seeping groundwater wear at the crest. Researchers study the intertwined effects of waves and groundwater on erosion with three-dimensional models of coastal bluffs based on overhead images captured by drone flights.

Collin Roland, graduate student, and Lucas Zoet, assistant professor, GeoscienceDJI Phantom 4 Advanced unmanned aerial vehicle

5 The spines armoring the leg of a tiny, newly described species of huntsman spider, Zalmoxis adze, are a remarkable work of sexual dimorphism theyre completely absent in females. While leg details were an important way to differentiate this spider as a new species, little is known about how the heavy spikes serve males in the leaf litter on the forest floor of Papua New Guinea. But it may be very showy or very violent.

Guilherme Gainett, graduate student, and Prashant P. Sharma, assistant professor, Integrative BiologyField emission scanning electron microscope

6 Flowers stand in for healthy breast tissue in this mammography image, while added calcifications Can you spot them all? represent the sort features doctors look for in X-ray images in an effort to catch breast cancer in early, treatable stages. UWMadison researchers are working to improve detection of patterns of tiny calcifications for faster, safer, more effective diagnosis.

Ran Zhang, scientist, and Dalton Griner, graduate student, Medical PhysicsSelenia Dimensions Mammography System

7 Crested geckos have clear, immovable eyelids, and a swipe of the tongue is the best way to keep them clean and moist. With veritable superpowers like the ability to see in the dark and climb vertical surfaces, geckos often serve as models for bio-inspired engineering.

Nisha Iyer, postdoctoral fellow, Wisconsin Institute for DiscoveryDigital camera

8 This snapshot of the sky contains thousands of distant galaxies, each containing billions of stars. The UWMadison physicists who made it were looking for the flash of the explosion of a single star, the potential source of a sub-atomic particle called a neutrino, spotted zipping through the Earth by the IceCube Neutrino Observatory at the South Pole. The distant galaxies, swirling billions of light years away, are all the harder to see because of nearby objects, like the pictured Helix Nebula.

Robert Morgan, graduate student, and Keith Bechtol, assistant professor, PhysicsDark Energy Camera and Victor M. Blanco Telescope

9 Thanks to a gene similar to one that makes some fish glow, leaves of the first transgenic that is, augmented with genes from another species hemp plants appear red when seen through a special filter, while leaves of an unaltered plant are a familiar green. Successfully engineering changes in hemp opens the door to alterations that could affect disease resistance, crop yield, fiber quality and cannabinoid compounds. It offers potential benefits for farmers, consumers and medical applications.

Michael Petersen, Edward Williams and Ray Collier, all staff of the Wisconsin Crop Innovation Center; and Frank McFarland, graduate student, AgronomySmartphone with specialized filter

10 This section of the head of an 11-day-old mouse embryo was expertly prepared to highlight blood vessels marked by the green and red of endothelial cells and laminin protein, respectively in the developing brain (the heart-shaped structure at the center). The vessels are particularly dense at the lower end of the two black slits that will become nostrils, where tissue is fusing together to form the upper lip. If the tissue fails to fuse, the mouse will be left with a birth defect studied by the researchers in the lab that produced the image: a cleft lip.

Miranda R. Sun, research specialist, Comparative Biosciences, School of Veterinary MedicineEpifluorescence microscope

Combining more than 90,000 individual images taken by five satellites two American, one Japanese and two from the European Space Agency perched 22,000 miles above the Earth makes for an animated view of global weather patterns. Strong storms span many days, and seasonal shifts come and go as the sunlight over the poles waxes and wanes and the planet spins from March 2019 to March 2020.

Rick Kohrs, instrument technologist, Space Science and Engineering CenterGeostationary satellites

Neural stem cells switch from a dormant to an active very active, in many cases state in this video from the lab of Neuroscience Professor Darcie Moore. The vigorous wigglers are starting a protein-maintenance program critical for efficient activation and differentiation into health brain cells.

Chris Morrow and Tiaira Porter, graduate students, NeuroscienceConfocal microscope

CONTINUED FROM ABOVE

There was enthusiastic support right out of the gate, and that enthusiasm has grown year after year, says Devitt, once editor of The Why Files and the recently retired director of research communications at UWMadison. Sharing science through imagery is another way to show how science works, and what you can learn from getting a close-up view of nature. And we all love to see something new and amazing.

The contest winners along with a slideshow of all entries are typically displayed each fall in the McPherson Eye Research Institutes Mandelbaum & Albert Family Vision Gallery on the ninth floor of the Wisconsin Institutes for Medical Research, 1111 Highland Ave. An exhibit will be scheduled and announced as activity on campus allows.

The 2020 winners show off the breadth of research and technical and scientific expertise at UWMadison. The images were captured by experts in their scientific fields, trainees, students and curious amateurs, using flying drones, smartphones, cutting-edge electron microscopes and Earth-facing satellites orbiting tens of thousands of miles away.

Their subjects are both everyday and ephemeral, large enough to encompass billions of stars, and more minuscule than an ant.

The Cool Science Image Contest helps recognize the technical and creative skills required to capture images or video that document science or nature, and benefits from sponsorship by Madisons Promega Corp., with additional support from DoIT Digital Publishing and Printing Services and the UWMadison Division of the Arts.

Winning entries are shared widely on UWMadison websites and in public exhibitions, and all entries are showcased in a slide show at the Wisconsin Science Festival.

Share via Facebook

Share via Twitter

Share via Linked In

Share via Email

Continue reading here:
Photo gallery The winners: Cool Science Images 2020 - University of Wisconsin-Madison

Biochemistry

Researchers are developing a diagnostic test that predicts the advanced stages of COVID-19 patients – News-Medical.Net

A research team from the University of Valencia, led by Professor Juan Saus from the Department of Biochemistry and Molecular Biology, is developing a project to provide the healthcare system with a diagnostic test that anticipates the entry into advanced stages of patients with COVID-19 and a scalable oral treatment for the disease.

The proposal has the support of the Valencian Government, within the call "Capacities of the Valencian System of Innovation in the fight against COVID-19", which finances actions that provide innovative solutions to the new coronavirus.

Goodpasture syndrome has been the subject of study by the research group led by Juan Saus at the University of Valencia since 1988. It is a pulmonary haemorrhage with kidney failure that currently manifests itself very sporadically and that, thanks to new discoveries made by Saus' team, has given way to a therapeutic proposal for COVID-19.

GPBP (Goodpasture antigen binding protein), when overexpressed and accumulates outside the cell, causes a destructuring of the microenvironment and transforms thin membranous structures into thick fibrous walls that make it difficult for oxygenation and blood purification in the lung and kidney."

Juan Saus, Professor, Department of Biochemistry and Molecular Biology, University of Valencia

"This established the basis for the development of EMTEST, a prototype to measure GPBP in blood and T12, a compound specifically designed to inhibit it", explains Juan Saus.

The research team observed that GPBP accumulates in the lungs of patients with a condition of severe respiratory distress called adult respiratory distress syndrome (ARDS), caused by infections or sepsis.

"There are increasing amounts of evidence that a sepsis with a predominance of lung involvement is the cause of fatality in COVID-19", explains Saus.

"With sepsis, antibacterial or antiviral treatments are not effective enough in stopping the process. Once ARDS has been triggered in COVID-19 patients, a treatment that eliminates the coronavirus is not expected to significantly modify the fatal course of the disease", concludes the expert.

For this reason, the project wants to use EMTEST to measure GPBP in the blood of COVID-19 patients and anticipate the appearance of ARDS. Then, with controlled GPBP levels, administer T12 to COVID-19 patients at risk of respiratory distress to avoid the onset of this disease.

"With this proposal we want to develop a diagnosis of the imminence of ARDS and a specific treatment to improve the survival of people with COVID-19 and avoid collapses in the Health System", says Juan Saus.

Read the original post:
Researchers are developing a diagnostic test that predicts the advanced stages of COVID-19 patients - News-Medical.Net